Primary cutaneous B-cell lymphomas: Part II. Therapy and future directions Journal Article


Authors: Suarez, A. L.; Querfeld, C.; Horwitz, S.; Pulitzer, M.; Moskowitz, A.; Myskowski, P. L.
Article Title: Primary cutaneous B-cell lymphomas: Part II. Therapy and future directions
Abstract: The choice of therapy for primary cutaneous B-cell lymphoma (PCBCL) relies on correct histopathologic classification and the exclusion of systemic disease. In part II of this continuing medical education article, we will review the available therapies for the different types of PCBCL. Primary cutaneous follicle center lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma (PCMZL) are indolent tumors with an excellent prognosis. They are managed similarly with local therapy, such as radiotherapy or surgical excision, for isolated disease and observation for asymptomatic multifocal presentations. Relapses are common in both PCFCL and PCMZL, but overall survival remains excellent. Primary cutaneous diffuse large B-cell lymphoma (both leg type and other) has a much poorer prognosis than indolent PCBCL, and it often requires an aggressive approach with radiation therapy and/or multiagent chemotherapy. Investigational approaches hold promise for the treatment of these malignancies, particularly primary cutaneous diffuse large B-cell lymphoma. © 2013 by the American Academy of Dermatology, Inc.
Keywords: cancer chemotherapy; cancer surgery; primary tumor; alpha interferon; rituximab; imiquimod; radiotherapy; steroid; chlormethine; b cell lymphoma; lymphoma; therapy; chlorambucil; clobetasol; skin lymphoma; primary cutaneous b-cell lymphoma; primary cutaneous diffuse large b-cell lymphoma; primary cutaneous follicle center lymphoma; primary cutaneous marginal zone lymphoma; primary cutaneous b cell lymphoma; primary cutaneous diffuse large b cell lymphoma leg type
Journal Title: Journal of the American Academy of Dermatology
Volume: 69
Issue: 3
ISSN: 0190-9622
Publisher: Mosby Elsevier  
Date Published: 2013-09-01
Start Page: 343.e1
End Page: 343.e11
Language: English
DOI: 10.1016/j.jaad.2013.06.011
PROVIDER: scopus
PUBMED: 23957985
DOI/URL:
Notes: --- - "Export Date: 1 October 2013" - "CODEN: JAADD" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Melissa P Pulitzer
    203 Pulitzer
  2. Steven M Horwitz
    645 Horwitz
  3. Alison Moskowitz
    339 Moskowitz
  4. Patricia Myskowski
    216 Myskowski